Published on Friday, September 07, 2007
With $3.82 million in second round investment funding, BioVigilant Systems is moving ahead with plans to manufacture its instantaneous microbial detection instruments for use in pharmaceutical production.
The company is now in discussions with a consortium of drug makers that includes Alcon, Amgen, Bayer, DSM Pharmaceuticals, Eli Lilly, Genentech, GlaxoSmithKline and Johnson & Johnson. The consortium is testing the detectors for use in preventing contamination at critical points in the production process.
BioVigilant, 2005 W. Ruthrauff Road, is also exploring the Asian market. Chief Executive Officer Dewey Manzar said he has been meeting with pharmaceutical makers and optical system manufacturers in Japan, "where we’ve found a very good reception."
Copyright © 2009 Inside Tucson Business